Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis

Journal of Neuroscience

Volumn 26, Issue 9, 2006, Pages 2467-2473

  Kiaei, Mahmoud ^a   Petri, Susanne ^a   Kipiani, Khatuna ^a   Gardian, Gabrielle ^a   Choi, Dong Kug ^b   Chen, Junyu ^a   Calingasan, Noel Y ^a   Schafer, Peter ^c   Muller, George W ^c   Stewart, Charles ^d   Hensley, Kenneth ^d   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Konkuk University   (South Korea)

^c CELGENE CORPORATION   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

FasL; G93A; Lenalidomide; SOD1; Thalidomide; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; LENALIDOMIDE; MESSENGER RNA; PROTEIN FASL; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIFE CYCLE; LUMBAR SPINAL CORD; MALE; MOTONEURON; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TRANSGENIC MOUSE; WEIGHT REDUCTION; ADULT; AGED; ANALYSIS OF VARIANCE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SURVIVAL; TIME;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOTOR ACTIVITY; NEURONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROTAROD PERFORMANCE TEST; SUPEROXIDE DISMUTASE; SURVIVAL; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 33645642112     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5253-05.2006     Document Type: Article

References (42)

1. Almer G, Vukosavic S, Romero N, Przedborski S (1999) Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 72:2415-2425.
2. Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, Chen C, Przedborski S (2001) Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49:176-185.
3. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322.
4. Boireau A, Bordier F, Dubedat P, Peny C, Imperato A (1997) Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci Lett 234:123-126.
5. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18:327-338.
6. Consilvio C, Vincent AM, Feldman EL (2004) Neuroinflammation, COX-2, and ALS - a dual role? Exp Neurol 187:1-10.
7. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163:380-386.
8. Elliott JL (2001) Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 95:172-178.
9. Ghezzi P, Mennini T (2001) Tumor necrosis factor and motoneuronal degeneration: an open problem. Neuroimmunomodulation 9:178-182.
10. Ghezzi P, Bernardini R, Giuffrida R, Bellomo M, Manzoni C, Comoletti D, Di Santo E, Benigni F, Mennini T (1998) Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. Eur Cytokine Netw 9:139-144.
11. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264:1772-1775.
12. Hall ED, Oostveen JA, Gurney ME (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23:249-256.
13. Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82:365-374.
14. Hensley LL, Ranganathan G, Wagner EM, Wells BD, Daniel JC, Vu D, Semenkovich CF, Zechner R, Kern PA (2003) Transgenic mice expressing lipoprotein lipase in adipose tissue. Absence of the proximal 3′-untranslated region causes translational upregulation. J Biol Chem 278:32702-32709.
15. Hirano A (1996) Neuropathology of ALS: an overview. Neurology 47:S63-S66.
16. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2005a) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191:331-336.
17. Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, Beal MF (2005b) Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 93:403-411.
18. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2006) Celastrol blocks motor neuron cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegenerative Dis, in press.
19. Kriz J, Nguyen MD, Julien JP (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10:268-278.
20. Leigh PN, Ray-Chaudhuri K (1994) Motor neuron disease. J Neurol Neurosurg Psychiatry 57:886-896.
21. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288:335-339.
22. Moreira, A. L. Sampaio, E. P. Zmuidzinas, A. Frindt, P. Smith, K. A. Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor αby enhancing mRNA degradation. J Exp Med 177:1675-1680.
23. Munoz-Fernandez MA, Fresno M (1998) The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 56:307-340.
24. Nagata S (1997) Apoptosis by death factor. Cell 88:355-365.
25. Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33:29-55.
26. Nguyen MD, Julien JP, Rivest S (2001) Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1β in neurodegeneration. Ann Neurol 50:630-639.
27. Pinkoski MJ, Brunner T, Green DR, Lin T (2000) Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 278:G354-G366.
28. Pinkoski MJ, Droin NM, Green DR (2002) Tumor necrosis factor α upregulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation. J Biol Chem 277:42380-42385.
29. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T (2000) Circulating levels of tumour necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 287:211-214.
30. Raoul C, Estevez AG, Nishimune H, Cleveland DW, deLapeyriere O, Henderson CE, Haase G, Pettmann B (2002) Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 35:1067-1083.
31. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 92:689-693.
32. Robertson J, Beaulieu JM, Doroudchi MM, Durham HD, Julien JP, Mushynski WE (2001) Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-α. J Cell Biol 155:217-226.
33. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62.
34. Schiffer D, Cordera S, Cavalla P, Migheli A (1996) Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci [Suppl] 139:27-33.
35. Siddique T, Nijhawan D, Hentati A (1996) Molecular genetic basis of familial ALS. Neurology 47:S27-S34.
36. Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13:151-153.
37. Tewari M, Dixit VM (1996) Recent advances in tumor necrosis factor and CD40 signaling. Curr Opin Genet Dev 6:39-44.
38. Ugolini G, Raoul C, Ferri A, Haenggeli C, Yamamoto Y, Salaun D, Henderson CE, Kato AC, Pettmann B, Hueber AO (2003) Fas/tumor necrosis factor receptor death signaling is required for axotomy-induced death of motoneurons in vivo. J Neurosci 23:8526-8531.
39. Venters HD, Dantzer R, Kelley KW (2000) A new concept in neurodegeneration: TNF-α is a silencer of survival signals. Trends Neurosci 23:175-180.
40. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
41. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105-1116.
42. Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80:158-167.